RxDoctor Payments Data

Muhammad Khan, MD

Neurology · Rochester Hills, MINPI 1558384693

Payments from drug & device makers

$64,084in general payments, 2019–2025

Across 148 payments — averaging $433.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$37K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$18K
  • Acadia Pharmaceuticals Inc$5K
  • AbbVie$517
  • UCB, Inc.$393
  • Pfizer$322
  • plus $2K from 28 others

What the payments were for

  • Speaking & faculty fees$231%
  • Food & beverage$3,31199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,084 in reported general payments places this provider in the 85th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$79,220
Medicare patients
196
Services billed
584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Memantine Hcl167$7,103
Primidone66$3,922
XareltoRivaroxaban25$3,443
Donepezil Hcl79$1,773
Escitalopram Oxalate58$1,424
Carbidopa-Levodopa ErCarbidopa/Levodopa13$1,145
Oxcarbazepine12$1,134
Sumatriptan Succinate21$1,101
Lamotrigine46$1,095
Ropinirole Hcl57$1,082
Gabapentin86$1,059
Nortriptyline Hcl33$880
Levetiracetam33$830
Propranolol Hcl ErPropranolol Hcl17$818
Carbidopa-LevodopaCarbidopa/Levodopa18$724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Upsher-smith Laboratories LLCTopiramate$13$42444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 652 neurology providers in Michigan.

Other neurology in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →